MRI scans are strong diagnostics with high-definition images of what lies inside a body. Strong magnetic fields require precaution, as brought out by an instance where a young woman suffered very serious injuries due to an oversight in a metallic core within a silicone sex toy that she happened to have before the MRI scan. This makes a stark reminder about the potentially deadly consequences of missing metal objects when such procedures are being performed. In April 2023, a 23-year-old woman went into an MRI with a silicone plug containing a metal core that was not known.

She thought that the item is made entirely out of silicone according to the advertising. However, the strong magnetic field of the MRI machine interacted with the hidden metal, dragging the object through her body and causing excruciating pain. According to reports from the U.S. Food and Drug Administration (FDA), the scene was harrowing, with the woman screaming in agony and requiring immediate hospitalization. Despite pre-scan screenings, which are routine prior to a scan, the patient did not inform the facility that the object existed because he presumed it was purely non-metallic. This caused serious injuries that led to the patient's law suit against the manufacturer for deceitful misrepresentations of material content.

MRI machines employ magnets between 0.5 to 3 Tesla (T). This is thousands of times stronger than the Earth's magnetic field. The tremendous force causes ferromagnetic materials, like iron and nickel, to be magnetized quickly and become strongly attracted toward the magnet. Objects as small as hairpins or paper clips will accelerate at 40 miles per hour inside the magnetic field.

The force can lead to catastrophic injuries in items lodged within the body, such as metallic implants or foreign objects. Metallic cores within devices, like pacemakers or intrauterine devices, must be disclosed to radiologists to prevent such complications.

How Metal Objects Interact with MRI Fields?

On these claims, Dr. Adam Taylor, a specialist in human anatomy, weighed his words in a international health website and added that the distance away and mass of this object would increase its velocity towards that of sound, "The acceleration would be phenomenal, but with a metallic core, it can't go anywhere near supersonic speeds. As for the size, the magnetic acceleration to the internal soft tissues would ensure that there could be severe intracranial trauma."

The injuries inflicted in this case likely involved damage to major blood vessels, nerves, or organs, highlighting the devastating impact of even minor oversight during an MRI scan.

This is not an isolated case. There are documented cases of metallic objects causing serious damage during MRI scans with a 65-year-old man with schizophrenia swallowed metal objects, including sockets and a hinge pin. The powerful magnetic field during an MRI scan caused the objects to rupture his stomach, resulting in serious injuries.

A toddler who ingested 11 small magnets perforated his bowel while undergoing a scan, making his case unique. In another deadly but extremely rare incident, there have been people who hide a firearm on themselves during MRI procedures. Magnetic attraction can trigger a discharge in a weapon and has led to some fatal injuries.

These cases emphasize the very strong need for adequate screening and patient education prior to an MRI.

Preventing MRI-Related Incidents

Medical professionals have been trained to avoid risks. This is by properly screening a patient for metallic objects. In general, most pre-scan protocols include:

• Patients are interrogated about implants, recent surgery or exposures at work related to metals.
• Radiologists sometimes use handheld metal detectors to search for hidden items.
• People who work with metal, like welders or machinists, will need additional testing to detect microscopic metal fragments within soft tissues or eyes.

The case emphasizes the importance of product labeling by manufacturers, especially those products that are likely to unintentionally cause harm to health. The patient's assumption that her device was 100% silicone points to a larger problem in consumer markets with misinformation.

It also reminds the patients to report any possible dangers to the medical professionals, no matter how the objects look non-metallic. In sensitive cases, patients can request private discussions with healthcare providers to ensure safety without discomfort.

In the end, it is a joint effort from manufacturers, healthcare professionals, and patients that can prevent such tragedies. Manufacturers must ensure truthful marketing, while healthcare providers should educate patients about the dangers of metal objects in MRI settings. For patients, understanding the risks and actively participating in pre-scan disclosures can be lifesaving.

This young woman's experience is a sobering example of the unforeseen dangers posed by MRI machines when precautions are overlooked. It serves as a wake-up call to address gaps in patient awareness, medical protocols, and product transparency. By learning from this incident, the medical community and the public can work together to ensure MRI scans remain a safe and effective diagnostic tool.

Irish middle-distance runner and two-time Olympian Ciara Mageean has died at the age of 34 after battling stage 4 bowel cancer. Her death, announced by her family on November 1, comes 16 months after she publicly revealed her diagnosis.

Mageean represented Ireland at the 2016 Rio and 2020 Tokyo Olympic Games. She won the women's 1,500m gold at the 2024 European Athletics Championships in Rome, becoming only the second Irish athlete to win an individual European title.

Her family announced her death in a statement on social media, saying, "At 6:30am this morning, Ciara lost her battle with cancer surrounded by her loved ones."

The athlete had revealed her cancer diagnosis in July 2025. In a subsequent interview with Irish broadcaster RTÉ, she spoke about the symptoms she initially noticed but how she attributed them to digestive problems.

"I would get up in the morning and I would need the toilet four times. I thought, 'That's not normal,'" she said.

She also described experiencing abdominal cramps and initially wondered whether something she had eaten had upset her stomach.

"I kept finding logical reasons for it, which many people would. I thought, 'Oh great, on top of everything else, I have an irritable bowel.'"

Mageean said her partner, Thomas Moran, encouraged her to seek medical advice. Further investigations revealed that she had stage 4 bowel cancer, which had spread to her liver and lungs.

Also read: India Cancer Drug Price Cuts: New Analysis Reveals 159 Out Of 643 Brands See No Reduction

Bowel Cancer Symptoms In Young Adults

Bowel cancer, also called colorectal cancer, develops in the colon or rectum. Although the risk increases with age, younger adults can also develop the disease. According to the NHS, symptoms can include:

• Changes in bowel habits: Chronic diarrhoea, constipation, softer stools or needing to use the toilet more frequently than usual.
• Blood in stools: Blood may appear bright red or make stools look dark or black.
• Abdominal pain: Persistent stomach cramps, discomfort or bloating.
• Feeling that the bowel has not emptied completely: A continuing urge to pass stools even after using the toilet.
• Unexplained weight loss: Losing weight without changes in diet or physical activity.
• Constant fatigue: Feeling unusually tired or breathless, sometimes due to anaemia caused by blood loss.

Also read: Colorectal Cancer Rates Rising in US Across Nearly All Age Groups After 20 Years of Decline

Why Bowel Cancer Can Be Overlooked In Younger People

One challenge in diagnosing bowel cancer in younger adults is that its symptoms can overlap with common digestive conditions like irritable bowel syndrome (IBS), haemorrhoids and inflammatory bowel disease.

Changes in bowel habits, abdominal cramps and bloating may therefore be attributed to dietary changes, stress or gastrointestinal infections.

However, unexplained symptoms should be assessed clinically. Rectal bleeding, ongoing changes in bowel habits, unexplained weight loss and fatigue should not automatically be attributed to benign digestive problems.

A family history of colorectal cancer, particularly in a close relative diagnosed at a young age, can also increase a person's risk.

Doctors may recommend blood tests to check for anaemia, stool tests such as the faecal immunochemical test (FIT), or further investigations including a colonoscopy, depending on the symptoms and clinical assessment.

An experimental pancreatic cancer vaccine triggered an immune response against genetic mutations related to cancer in nearly 99% of patients according to a Phase 2 clinical trial. This has offered a new treatment strategy in tackling one of the deadliest cancers.

The vaccine, called camupepimut, is designed to train the immune system to attack cancer cells carrying mutations in the KRAS gene. The findings, published in Nature Medicine, come from a randomised trial led by researchers at Mayo Clinic.

KRAS mutations are found in approximately 90% of pancreatic ductal adenocarcinomas, the most common type of pancreatic cancer. These mutations help cancer cells grow and survive, making the gene an important target for researchers developing new treatments.

The trial included 144 patients with KRAS-mutated pancreatic cancer who had undergone surgery and chemotherapy. None had visible signs of cancer on imaging when they entered the study. Researchers randomly assigned 96 patients to receive the vaccine, while 48 were placed in an observation group.

Of the 90 vaccinated patients whose immune responses could be evaluated, 89, or 98.9%, developed increased T-cell responses against mutated KRAS. In more than 80% of these patients, the immune response was over nine times stronger than before vaccination.

How Does The Pancreatic Cancer Vaccine Work?

Also read: Top Neurologist Says Stroke Could Be First Sign of Undiagnosed Cancer: Red Flags to Know | Interview

Camupepimut is an investigational therapeutic cancer vaccine designed to target seven common mutations in the KRAS gene.

Unlike preventive vaccines that protect people against infections that can cause cancer, therapeutic cancer vaccines aim to help the immune system recognise and attack cancer cells.

The vaccine is designed to direct an immune response towards the body's lymph nodes, where immune cells are activated. It stimulates T cells, a type of white blood cell that can identify and destroy abnormal cells carrying specific mutations.

The researchers found that the vaccine activated both CD4 and CD8 T cells. These immune cells play different roles in recognising abnormal cells and coordinating attacks against them. Also, among patients who could be evaluated at least 46 weeks after starting vaccination, 95.5% continued to show a detectable KRAS-specific T-cell response.

"Historically, pancreatic cancer has been very difficult to treat with immunotherapy," said Ben George, a Mayo Clinic medical oncologist and lead author of the study.

"What is encouraging is that we were able to generate a strong immune response against KRAS mutations in nearly every patient we evaluated. In an exploratory analysis, patients with greater immune responses to the vaccine appeared protected with longer disease-free survival times."

Did The Vaccine Prevent Pancreatic Cancer From Returning?

Despite the strong immune response, the trial did not establish that camupepimut prevents pancreatic cancer recurrence.

There was no significant difference in survival without disease between the vaccinated and observation groups, which was the trial's primary outcome.

Median disease-free survival was 23.8 months among patients who received the vaccine, compared to 21.2 months in the observation group.

Researchers did, however, find a link between stronger immune responses induced by vaccines and longer periods without disease recurrence.

The researchers also identified possible differences in response based on patients' previous treatment. Those who had received radiation therapy developed weaker immune responses related to KRAS because radiation was associated with lower levels of lymphocytes, which are important immune cells.

These findings may help researchers identify which patients are more likely to benefit from the vaccine, but they are not yet sufficient to guide treatment decisions.

"We've shown that we can teach the immune system to recognize these KRAS mutations," Dr George said. "The next step is finding out whether doing that can change the course of the disease for patients."

Currently, researchers are planning a Phase 3 clinical trial to investigate whether camupepimut can improve outcomes for patients with pancreatic cancer.

India’s latest cancer drug price revision has reduced the maximum retail prices (MRPs) of several anti-cancer medicines. While the average price reduction comes around to be more than 50%, roughly one in four of the listed drugs still remain unchanged.

Also, the overall decline across all products is only 13.8%, according to an analysis by the Working Group on Access to Medicines and Treatments.

The analysis examined 643 anti-cancer drugs that were a part of the revised price list issued by the National Pharmaceutical Pricing Authority (NPPA). 484 products, or 75.27%, recorded a price reduction, while 159 products, accounting for 24.73%, remained unchanged.

Why Is Overall Price Reduction In Cancer Drugs Only 13.8%?

Also read: Top Neurologist Says Stroke Could Be First Sign of Undiagnosed Cancer: Red Flags to Know | Interview

Among products that became cheaper, the average price reduction was 50.78%. But when the combined listed MRPs of all 643 products were compared, the overall reduction was only 13.8%.

The difference between the two figures reflects the fact that many expensive cancer medicines have remained unaffected.

According to the working group’s analysis, the combined listed MRP of all 643 products fell from approximately ₹2.51 crore to ₹2.17 crore, marking a reduction of around ₹34.57 lakh.

However, the 159 products that recorded no price reduction accounted for 86.2% of the combined revised MRP value of the entire list.

“Of course, average can be misleading,” said KM Gopakumar, researcher with the Third World Network and co-convenor of the working group. “This weighted reduction gives us much more a realistic view.”

Expensive Cancer Drugs Remain Unchanged

Also read: Cancer Drug Prices Slashed For 543 Brands From Nov 9, But A Blockbuster Drug That Treats 21 Cancers Remains Untouched

The analysis found that several expensive cancer drug brands, including medicines manufactured by multinational pharmaceutical companies, retained their earlier MRPs. These include:

• Keytruda (pembrolizumab): The listed price remains ₹2,16,500 for a 100 mg injection.
• Tagrisso (osimertinib): The price remains approximately ₹4.16 lakh for a pack of 30 tablets.
• Avastin (bevacizumab): Roche’s 400 mg vial remains priced at ₹1,23,506.
• Alimta (pemetrexed): Eli Lilly’s 500 mg injection remains priced at ₹29,531.25.

The analysis also found that 110 of 122 products examined across 18 selected multinational pharmaceutical companies recorded no price reduction. Their average price reduction across all 122 products was just 1.3%.

On the other hand, several generic medicines recorded substantial cuts. For example, the price of a 400 mg bevacizumab vial sold as Bevacirel by Reliance Life Sciences fell by 83.27%, while Abbott Healthcare’s Bevacizab recorded an 86.26% reduction.

Call For Further Action

The Working Group on Access to Medicines and Treatments has urged the government to consider additional measures to improve access to expensive cancer medicines.

It has called for public health safeguards under Sections 92 and 100 of the Patents Act, which provide for compulsory licensing and government use of patented inventions in particular circumstances.

Such provisions can allow access to patented medicines under defined legal conditions when public health requirements warrant intervention.

The group has also questioned the trade margin framework, arguing that the margins remain high and that the government should disclose the calculations used to ascertain revised MRPs.

The NPPA introduced the latest intervention to address excessive trade margins and reduce the cost of cancer medicines.

Its October 28 list initially covered 543 brands, with subsequent updates expanding the coverage to 643 products.

The price revisions suggest that the overall impact remains limited because pricey drugs have not become cheaper. So patients who need expensive patented treatments, the latest price cuts may therefore offer little direct relief.